Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C
| Author | Mohammad Reza Zali | en |
| Author | Hamid Mohaghegh Shalmani | en |
| Author | Mohsen Norouzinia | en |
| Author | Amir Hooshang MohammadAlizadeh | en |
| Author | Azita Nowroozi | en |
| Author | Negar Behrouz | en |
| Issued Date | 2004-09-30 | en |
| Abstract | Background and Aim: Pegylation of interferon alfa-2a is a new modality for treatment of chronic hepatitis C. This clinical trial was conducted to evaluate the efficacy and safety of PEG IFN in combination with ribavirin in CHC patients.Methods: Fifty seven patients with HCV RNA in serum, persistently elevated ALT and chronic C hepatitis on liver biopsy enrolled to this study. The patients received PEG IFN 180 micg per week plus ribavirin 10-15 mg/kg per day.Results: HCV RNA was negative in 37 patients (74%) after three months of beginning of study (EVR) and SVR occurred in 50% of all patients.Conclusion: Peginterferon alfa-2a plus ribavirin is safe and effective in treatment of naïve patients and relapsers. | en |
| DOI | https://doi.org/ | en |
| Keyword | Hepatitis C | en |
| Keyword | Pegylated interferon alfa-2a | en |
| Keyword | Ribavirin | en |
| Keyword | Therapy | en |
| Publisher | Brieflands | en |
| Title | Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 70571-pdf.pdf
- Size:
- 33.19 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF